Adjuvant immunotherapy with BCG in treatment of regional-lymph-node metastases from malignant melanoma.

Despite current surgical therapy, about 80 per cent of patients with malignant melanoma metastatic to lymph nodes succumb to systemic metastatic disease. To determine if postoperative adjuvant immunization with BCG was an effective systemic treatment in these patients with microscopic subclinical metastatic disease, the clinical course of 42 patients treated by operation alone was compared with that of 84 treated by operation and BCG. At two years, the incidence of metastasis in BCG-treated patients was half that of the control group. BCG was more effective in patients with a smaller tumor burden at the time of initial surgical treatment. In patients receiving BCG adjuvant therapy, 90 per cent with microscopic disease in one lymph node appeared free of disease as compared to 40 per cent with macroscopic disease in multiple nodes. In patients with recurrences, an immunotherapeutic effect was demonstrated by a delay of six months in the time to recurrence. Thus, BCG immunotherapy appears to have an inhibiting effect on the "micrometastases" of malignant melanoma.

[1]  R. Bast,et al.  BCG and cancer (first of two parts). , 2010, The New England journal of medicine.

[2]  L. Nathanson.  Use of BCG in the treatment of human neoplasms: a review. , 1974, Seminars in oncology.

[3]  D. W. Weiss,et al.  Shared antigens between Mycobacterium bovis (BCG) and neoplastic cells. , 1974, Journal of the National Cancer Institute.

[4]  M. Silverstein,et al.  BCG lmmunotherapy of Malignant Melanoma: Summary of a Seven-year Experience , 1974, Annals of surgery.

[5]  L. Einhorn,et al.  Chemoimmunotherapy of disseminated malignant melanoma with dimethyl triazeno imidazole carboxamide and bacillus calmette--guérin. , 1974, The New England journal of medicine.

[6]  M. Silverstein,et al.  Complications of BCG immunotherapy in patients with cancer. , 1973, The New England journal of medicine.

[7]  E. Hersh,et al.  Active immunotherapy with B.C.G. for recurrent malignant melanoma. , 1973, Lancet.

[8]  R. W. Baldwin,et al.  BCG Immunotherapy of Pulmonary Growths from Intravenously Transferred Rat Tumour Cells , 1973, British Journal of Cancer.

[9]  B. Zbar,et al.  Immunotherapy of Cancer: Regression of Tumors after Intralesional Injection of Living Mycobacterium bovis , 1971, Science.

[10]  D. Morton,et al.  Immunotherapy experiments with a methylcholanthrene-induced guinea pig liposarcoma. , 1971, Journal of the National Cancer Institute.

[11]  A. Ballantyne.  Malignant melanoma of the skin of the head and neck. An analysis of 405 cases. , 1970, American journal of surgery.

[12]  H. Goldsmith,et al.  Incontinuity versus discontinuous lymph node dissection for malignant melanoma , 1970 .

[13]  J. Shah,et al.  Prognostic significance of lymph node dissection in the treatment of malignant melanoma , 1970, Cancer.

[14]  D. Morton,et al.  Immunological factors which influence response to immunotherapy in malignant melanoma. , 1970, Surgery.

[15]  B. Zbar,et al.  Immunotherapy of Cancer: An Experimental Model in Syngeneic Guinea Pigs , 1970, Science.

[16]  G. Mathé,et al.  Active immunotherapy for acute lymphoblastic leukaemia. , 1969, Lancet.

[17]  W. Clark,et al.  The histogenesis and biologic behavior of primary human malignant melanomas of the skin. , 1969, Cancer research.

[18]  J. Cantin,et al.  Local failure in the treatment of melanoma. The Janeway lecture, 1966. , 1967, The American journal of roentgenology, radium therapy, and nuclear medicine.

[19]  J. Stehlin,et al.  MELANOMA OF THE EXTREMITIES; EXPERIENCES WITH CONVENTIONAL TREATMENT AND PERFUSION IN 339 CASES. , 1965, American journal of surgery.

[20]  J. Fortner,et al.  Primary Malignant Melanoma on the Trunk: An Analysis of 194 Cases , 1965, Annals of surgery.